Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and ...

SAN FRANCISCO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis

Related Keywords

Boston ,Massachusetts ,United States ,Ukraine ,Snehav Gupta ,Yali Zhu ,Jiayi Zhou ,Sacha Satram ,Rachel Wong ,Sasha Damouni Ellis ,Senior Research ,Corporate Affairs Officer ,Nasdaq ,Vir Biotechnology Inc ,Exchange Commission ,Alnylam Pharmaceuticals Inc ,Head Of Research ,Health Economics Outcomes Research At Vir Biotechnology ,American Association ,Liver Diseases ,Liver Meeting ,Phil Pang ,Executive Vice President ,Chief Medical Officer ,Interim Head ,Poster Session ,Senior Research Associate ,Clinical Pharmacology ,Clinical Immunology Scientist ,Senior Director ,Brii Biosciences ,Health Economics ,Outcomes Research ,Enhanced Stabilization Chemistry Plus ,Alnylam Pharmaceuticals ,Private Securities Litigation Reform Act ,Media Carly Scaduto Senior Director ,Media Relations ,Sasha Damouni Ellis Executive Vice President ,Chief Corporate Affairs ,Region ,